Suchandrima Saha

Suchandrima Saha

Auto-generated profile, based on publicly available information

Suchandrima Saha

Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SSSuchandrima Saha
Suchandrima Saha
MGMonisankar Ghosh
Monisankar Ghosh
JLJinyu Li
Jinyu Li
AWAsher Wen
Asher Wen
Lorenzo GalluzziLorenzo Galluzzi
Lorenzo Galluzzi
DMDavid C Montrose
David C Montrose
Serine is critical for supporting cancer metabolism, and depriving malignant cells of this nonessential amino acid exerts antineoplastic effects, in large part, through disrupting metabolic pathways. Given the intricate relationship between cancer metabolism and the immune system, the metabolic defects imposed by serine deprivation might impact tumor-targeting immunity. In this study, we demonstrated that restricting endogenous and exogenous sources of serine in colorectal cancer cells results in mitochondrial dysfunction, leading to mitochondrial DNA (mtDNA) accumulation in the cytosol and consequent cGAS-STING1-driven type I IFN secretion. Depleting mtDNA or blocking its release attenuated cGAS-STING1 activation during serine deprivation. In vivo studies revealed that serine deprivation limits tumor growth, accompanied by enhanced type I IFN signaling and intratumoral infiltration of immune effector cells. Notably, the tumor-suppressive and immune-enhancing effects of serine restriction were impaired by T-cell depletion and IFN receptor blockade. Moreover, disrupting cGAS-STING1 signaling in colorectal cancer cells limited the immunostimulatory and tumor-suppressive effects of serine deprivation. Lastly, serine depletion increased the sensitivity of tumors to an immune checkpoint inhibitor targeting PD-1. Taken together, these findings reveal a role for serine as a suppressor of antitumor immunity, suggesting that serine deprivation may be employed to enhance tumor immunogenicity and improve responsiveness to immune checkpoint inhibitors. Significance: Depriving cancer cells of serine provokes mitochondrial perturbations that induce cytosolic mitochondrial DNA accumulation and subsequent activation of cGAS-STING signaling, stimulating tumor-targeting immune responses that can be enhanced with PD-1 targeted therapy. See related commentary by Borges and Garg, p. 2569

19 March 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
SMSamantha C. Mulkeen
Samantha C. Mulkeen
SSSuchandrima Saha
Suchandrima Saha
CFCarmen R Ferrara
Carmen R Ferrara
VBVladimira Bibeva
Vladimira Bibeva
MWMichael Wood
Michael Wood
DMDavid C Montrose
David C Montrose
Diet is believed to be an important mediator of oncogenesis and response to anticancer therapies although no evidence-based dietary guidelines exist for patients with cancer. Limiting protein intake can suppress tumor growth by both inducing nutrient stress and enhancing antitumor immunity. However, little is known about the impact of reducing dietary protein on the efficacy of chemotherapy, the most widely used anticancer treatment. In this study, we present evidence that reducing protein intake in mice by 50% stops the growth of established tumors, in parallel with inducing a stress response and DNA damage. Further, a reduced protein (RP) diet enhances tumor regression upon treatment with 5-fluorouracil (5-FU). This effect is accompanied by elevated apoptosis and suppressed mitosis of tumor cells. Proteomic analysis of tumors revealed marked differences between 5-FU–treated mice fed a control diet and those fed an RP diet, including decreased abundance of proteins that mediate DNA repair and replication in mice consuming RP. In vitro studies mimicking amino acid changes found in tumors from RP-fed mice showed that cGAS/STING1 signaling, including transcription of Ifnb1, was maximally increased in 5-FU–treated cells cultured in modified amino acid medium. These findings correlated with enhanced immune cell influx into tumors from mice treated with 5-FU while consuming an RP diet, an effect that was causally linked to improved response to chemotherapy. Collectively, these findings suggest that reducing dietary protein in patients with cancer may enhance the efficacy of chemotherapy by promoting antitumor immunity.

18 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSuchandrima Saha
Suchandrima Saha
FVFabiola N. Velazquez
Fabiola N. Velazquez
FDFatemeh Dehpanah
Fatemeh Dehpanah
BBBrianna L. Bergfalk
Brianna L. Bergfalk
SMSamantha Mulkeen
Samantha Mulkeen
DMDavid C Montrose
David C Montrose
Deoxysphingolipids (deoxySLs) are a class of non-canonical sphingolipids that can adversely impact mitochondrial function. Mitochondrial disruption can activate the cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING1) pathway, and in turn, promote antitumor immunity. Here, we investigated whether inducing deoxySL accumulation in colon cancer cells drives immune-specific, antitumor effects. We show that depleting serine increased deoxySLs and enhanced immune cell infiltration in colon tumors, in parallel with suppressing tumor growth. Elevating tumor deoxySL levels through mutation of SPT in cells and feeding a high alanine diet to mice exerted similar effects, including immune-mediated tumor growth suppression. Work conducted in multiple in vitro systems identified deoxySLs as key triggers of cGAS-STING1 activation, an effect mediated by mitochondrial release of double-stranded DNA resulting from mitochondrial stress. Collectively, these findings provide the first evidence that deoxySLs can drive antitumor immunity and identify a previously unrecognized metabolic strategy for cancer therapy.